Positioned at the gateway of academic innovation, Integra has invested in game-changing advancements in diverse therapeutic fields that show vast commercial potential, including Oncology, Neurology, Pain & Anesthesia, Infectious Diseases, Inflammation and Ophthalmology. The company holds a portfolio of 11 companies in early to late stages of development
A late stage company with a unique lipid-based cytotoxic agent cytotoxic agent in preparations for review by FDA for marketing authorization.
A preclinical company developing novel monoclonal antibodies targeting novel immune-checkpoint mechanisms in oncology, focusing on the Nectin family of receptors.
A preclinical company developing novel antisense oligonucleotides for specific genetic mutations in Cytic Fibrosis, a disease with great unmet clinical needs.
HighRAD provides the first Intelligent Computer Assessment Support (iCASTM) system that delivers a trusted, automatic and enriched view of multi-organ imaging longitudinal data to improve healthcare outcomes and help stop disease progression.
A medical device company with breakthrough laser-based technology that reduces the size, complexity and cost of proton accelerators, marking a significant leap in radiation therapy.
A preclinical company with a unique formulation of the widely used anesthetic agent, Propofol, that provides a solution to the main drawback of the commercial product Diprivan, bacterial contamination.
A preclinical stage company that develops novel liposomal formulations of known drugs for post-surgical pain.
A preclinical company developing novel topical non-invasive formulations of approved drugs to ocular uses, targeting major disease states and clinical needs.
RNAble is developing novel compounds that alter RNA stability through modulation of RNA epitranscriptomics for the treatment of specific cancers and rare genetic diseases with nonsense mutations.
A Phase Ib company that develops a novel liposomal prodrug of a cytotoxic agent for cancer therapy.